GSK agreed to license Hutchmed’s KRAS-EGFR cancer drug for $110 million upfront, with potential biobucks payments of up to $1.185 billion tied to development and commercial milestones. The licensed asset is Hutchmed’s KRAS-EGFR antibody conjugate, positioning GSK to add a new mechanism into its oncology pipeline. The deal highlights how large-cap pharma is continuing to pay for next-generation targeting strategies rather than relying only on internal discovery, especially in antibody-drug and engineered biologics where differentiation depends on tumor biology selection and payload delivery. For Hutchmed, the upfront cash strengthens runway while the milestone structure transfers much of the later execution risk to the acquirer. Overall, the agreement reinforces that KRAS-linked oncology continues to attract cross-company partnering interest despite the modality and safety complexity involved in translating targeted constructs into clinical benefit.